COMPANY OVERVIEW

Leadership

Mr. JayJay Lee, CEO

Dr. Jungchae Lim, CSO

Dr. Alexcandre Joyeux, COO

Dr. Sangpil Lee, CTO

FatiAbGen is a leading antibody-based platform company with a broad clinical pipeline for Oncology and Allergy disease treatment using our best-in-class therapeutic antibodies.

FatiAbGen became a member of the JLABS family in 2023, strongly aligned with J&J's innovative portfolio.

In 2024, FatiAbGen established a FatiAbGen International GmbH in Basel Switzerland to accelerate business development for future out-licensing.

The two most advanced assets are:
- Collaboration with Duality Biologics to co-develop MSLN ADC with unique properties and strong data in mouse xenograft models of various solid tumor cancer
- Collaborate with Lonza to develop a Novel IgE backbone for allergy/asthma indications, with favorable properties compared to Xolair

We are seeking a global investor who is willing to co-invest with Korean VCs and CVCs for Series A.

FABP1-1013: Best-in-class Therapeutic Antibody for Allergies

IgE-mediated Allergic Reaction

- Allergen/IgE/FcεRI axis plays a large role in allergic symptoms
- FcεRI on mast cells is a potential target for allergy therapeutics



Drug Discovery Today: Disease Models (2015) 17-18, 37-44

Mode-of-Action of CγIgE

- Prophylactic benefit: Pre-binding to FcεRI
- Therapeutic benefit: Competitive binding activity and disruptive activity





In Vivo Efficacy of CγIgE in PCA Mouse Model

- Inhibitory effect of allergic response in a dose-dependent manner
- Non-inferior efficacy to omalizumab (no statistically significant difference)



The Novel CγIgE for Allergy Treatment

- FcεRI-targeting IgG/IgE Hybrid Immunoglobulin E
- Optimized for inhibiting allergy reactions
  - Heavy chain: $C\gamma_1$-$C\varepsilon_{2\text{-}4}$, each ~ 53 kDa
  - Light chain: C_κ, each ~ 12 kDa



- No undesirable cross-reactivity
  → Non-anaphylactogenic
- Protein expression/correct assembly (HC/LC)
  → High structural stability
  → Removal of 3 glycosylation sites
- Retain Fc biochemical characteristics of IgE
  → Binding to FcεRI (IgE receptor blocking)

In Vitro Efficacy of CγIgE

- Higher competitive binding activity (~10-fold) vs omalizumab
- Higher disruptive activity (~3-fold) vs omalizumab



FABP1-1013 vs Xolair (Omalizumab)



	Xolair	FABP1-1013
Format	IgG (Humanized)	IgE (Human)
Target	Free IgE	FcεRI/CD23
Affinity	~ 10^{-9} M	~ 10^{-10} M
Receptor Blocking	Indirect	Direct
Indication Application	Block IgE signaling	Block IgE signaling Target IgE receptor$^+$ cells
Anaphylaxis	Yes	No

FABDU03G-1024: Best-in-class Antibody-Drug Conjugate Targeting Mesothelin: Partnership with DualityBio 映恩生物

Mesothelin as a Cancer Target

- Highly expressed in solid tumors vs normal tissues
- Internalization capability for ADC
- No observable phenotype in MSLN KO mouse

Structure



Expression

Solid malignancy	Frequency
Mesothelioma	95 ~ 90%
Pancreatic cancer	80 ~ 85%
Ovarian cancer	60 ~ 65%
Cholangiocarcinoma	60 ~ 65%
Lung cancer	60 ~ 65%
Stomach cancer	50 ~ 55%
Colon cancer	40 ~ 45%
Esophageal cancer	35 ~ 40%
Breast cancer	25 ~ 30%

Binding Affinity of Anti-MSLN mAbs



Ab	K_D (nM)	R squared
Isotype control	3.38E-07	0.02507
Amatuximab	0.01143	0.9986
Anetumab	0.01859	0.9969
CSA0682	0.02079	0.9979
CSA1092	1.211	0.996
CSA1097	0.02567	0.9973

Internalization of Anti-MSLN mAbs (Live Cell Image)

- CSA1092: ~3 fold faster than reference mAb, anetumab (Bayer)
- CSA0682 & CSA1097: ~2 fold faster than reference mAb



Internalization of Anti-MSLN ADC (ICC)



In Vitro Efficacy of ADC Targeting MSLN



Specificity & Cross-reactivity of Anti-MSLN mAbs



Generation of ADC Targeting MSLN

- Generated using DualityBio's ADC platform (DITAC)
- Better therapeutic window with low toxicity and high efficacy



DITAC Technology

- Superior systemic stability
- Sustained tumor-selective drug release
- Diffusible payload in tumor microenvironment
- Efficient bystander killing
- Rapid systemic clearance

In Vivo Efficacy of ADC Targeting MSLN



CONTACT JayJay Lee | CEO | ceo@fatiabgen.com